Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $59.9 million versus the consensus estimate of $61.7 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $250-260 million, versus the consensus of $274.4 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Sysco raises mid-term targets, unveils $500M AI efficiency program
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
• Casey's General Stores (CASY) Tops Q1 EPS by 69c